- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Rosen Law Firm Encourages Corcept Therapeutics Investors to Secure Counsel Before Deadline
Investors who purchased Corcept stock between October 2024 and December 2025 may be eligible for compensation.
Mar. 31, 2026 at 2:05am
Got story updates? Submit your updates here. ›
A legal case over a pharmaceutical company's disclosures exposes the complexities of corporate transparency and investor protections.NYC TodayThe Rosen Law Firm, a global investor rights law firm, is reminding purchasers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025 of the important April 21, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Corcept made misleading statements about the clinical trials supporting its new drug application for relacorilant, a treatment for hypercortisolism.
Why it matters
The outcome of this lawsuit could have significant financial implications for Corcept Therapeutics and its investors. The case highlights the importance of transparency and accuracy in public company disclosures, especially around clinical trials and regulatory approvals.
The details
According to the lawsuit, Corcept represented that the key clinical trials for relacorilant provided 'powerful support' for the New Drug Application (NDA) submitted to the FDA. However, the lawsuit claims the FDA had repeatedly raised concerns about the adequacy of the clinical evidence, creating a material risk that the NDA would not be approved. When this information became public, investors allegedly suffered damages.
- The class period is from October 31, 2024 to December 30, 2025.
- The lead plaintiff deadline is April 21, 2026.
The players
Corcept Therapeutics Incorporated
A pharmaceutical company that develops and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders.
Rosen Law Firm
A global investor rights law firm that concentrates its practice in securities class actions and shareholder derivative litigation.
What they’re saying
“We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition.”
— Laurence Rosen, Founding Partner, Rosen Law Firm
What’s next
Investors who purchased Corcept stock during the class period have until April 21, 2026 to move the court to serve as lead plaintiff in the class action lawsuit.
The takeaway
This case highlights the importance of transparency and accuracy in public company disclosures, especially around clinical trials and regulatory approvals. Investors should carefully evaluate the qualifications and track record of any law firm representing them in a securities class action.
